All In Biotech

Drug Trial Radar · NCT04728893

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Apr 5, 2021

Primary completion

Jan 4, 2029

Study completion Jan 4, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

Conditions

  • Hematologic Malignancies
  • Waldenstroms Macroglobulinaemia
  • Non-Hodgkins Lymphoma
  • Chronic Lymphocytic Leukaemia

Interventions

  • NemtabrutinibDrug

    Nemtabrutinib tablets administered orally QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)Time frame: Up to ~56 days (Cycles 1-2, cycle = 28 days)
  2. Part 1: Number of participants experiencing adverse events (AEs)Time frame: Up to ~71 months
  3. Part 1: Number of participants discontinuing study treatment due to AEsTime frame: Up to ~42 months
  4. Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)Time frame: Up to ~61 months
  5. Part 2: ORR per Lugano criteria 2014 as assessed by ICRTime frame: Up to ~61 months
  6. Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICRTime frame: Up to ~71 months

Locations

121 sites in 22 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group ( Site 2728)

    Springdale, Arkansas · Recruiting

  • University of California San Diego Moores Cancer Center ( Site 2717)

    La Jolla, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)

    Torrance, California · Completed

  • Colorado Blood Cancer Institute ( Site 2726)

    Denver, Colorado · Recruiting

  • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)

    Louisville, Kentucky · Completed

  • Mayo Clinic - Rochester ( Site 2706)

    Rochester, Minnesota · Active not recruiting

  • Astera Cancer Care ( Site 2732)

    East Brunswick, New Jersey · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)

    Hackensack, New Jersey · Recruiting

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)

    Fargo, North Dakota · Completed

  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)

    Dallas, Texas · Recruiting

  • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)

    Spokane, Washington · Recruiting

  • FUNDALEU ( Site 0104)

    Caba, Argentina · Recruiting

  • Hospital Privado Universitario de Córdoba ( Site 0107)

    Córdoba, Argentina · Recruiting

  • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)

    Mendoza, Argentina · Completed

  • Hospital Aleman ( Site 0102)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Fundacion Estudios Clinicos ( Site 0112)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)

    Sydney, New South Wales, Australia · Completed

  • Box Hill Hospital ( Site 0203)

    Box Hill, Victoria, Australia · Recruiting

  • Sir Charles Gairdner Hospital ( Site 0200)

    Nedlands, Western Australia, Australia · Recruiting

  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)

    Rio de Janeiro, Brazil · Recruiting

  • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)

    São Paulo, Brazil · Active not recruiting

  • Hospital Paulistano - Amil Clinical Research ( Site 0311)

    São Paulo, Brazil · Recruiting

  • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)

    São Paulo, São Paulo, Brazil · Recruiting

  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)

    Calgary, Alberta, Canada · Recruiting

  • The Ottawa Hospital ( Site 0404)

    Ottawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)

    Toronto, Ontario, Canada · Recruiting

  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)

    Montreal, Quebec, Canada · Recruiting

  • Jewish General Hospital ( Site 0400)

    Montreal, Quebec, Canada · Recruiting

  • Anhui Provincial Hospital ( Site 2808)

    Hefei, Anhui, China · Active not recruiting

  • Peking University Third Hospital-Hematology ( Site 2827)

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)

    Chongqing, Chongqing Municipality, China · Completed

  • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)

    Guangzhou, Guangdong, China · Active not recruiting

  • Liuzhou People's Hospital ( Site 2817)

    Liuzhou, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital ( Site 2814)

    Nanning, Guangxi, China · Recruiting

  • Henan Cancer Hospital-hematology department ( Site 2802)

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Union Hospital ( Site 2816)

    Wuhan, Hubei, China · Recruiting

  • The Second Xiangya Hospital of Central South University ( Site 2820)

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital ( Site 2822)

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital ( Site 2823)

    Nanjing, Jiangsu, China · Recruiting

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.